

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (To be used for all correspondence after initial filing) <b>OFFICE OF THE ATTORNEY GENERAL</b> <b>TRADEMARK OFFICE</b> JUN 25 2002	Application Number	10/076,754
	Filing Date	February 12, 2002
	First Named Inventor	Emad S. Alnemri
	Group Art Unit	1646
	Examiner Name	
Attorney Docket No.		480140.432D3

RECEIVED



JUN 28 2002

TECH CENTER 1600/2900


**ENCLOSURES (check all that apply)**


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement; Form PTO-1449 <input checked="" type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
Remarks		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Individual Name	William T. Christiansen, Ph.D.	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	June 21, 2002	

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.		
Typed or printed name	John T. Oliver	
Signature		Date: June 21, 2002



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231.

Date June 21, 2002

John T. Oliver  
John T. Oliver

RECEIVED

JUN 28 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant : Emad S. Alnemri  
Application No. : 10/076,754  
Filed : February 12, 2002  
For : TRAIL RECEPTORS, NUCLEIC ACIDS ENCODING  
THE SAME, AND METHODS OF USE THEREOF

Art Unit : 1646  
Docket No. : 480140.432D3  
Date : June 21, 2002

Commissioner for Patents  
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicant wishes to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicant does not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserves the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicant's duty to disclose all information he is aware of which is believed relevant to the examination of the above-identified application, applicant believes that his invention is patentable.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Emad S. Alnemri

Seed Intellectual Property Law Group PLLC



---

William T. Christiansen, Ph.D.

Registration No. 44,614

WTC:jto

Enclosures:

Postcard

Form PTO-1449

Cited References (3)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092

Phone: (206) 622-4900

Fax: (206) 682-6031

D:\NrPortbl\iManage\JOHNO\295556\_1.DOC

RECEIVED


TECH CENTER 1600/2900

JUN 28 2002

Sheet 1 of 1

FORM PTO-1449  
(REV.7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
480140.432D3APPLICATION NO.  
10/076,754SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT  
Emad S. AlnemriFILING DATE  
February 12, 2002GROUP ART UNIT  
1646

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,261,801	07/17/01	Wei et al.	435	69.1	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK					
	AL					
	AM					
	AN					
	AO					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Mikayama et al., "Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor," <i>Proc. Natl. Acad. Sci. USA</i> 90:10056-10060, November 1993.
	AQ	Voet et al., <u>Biochemistry</u> , John Wiley & Sons, Inc., 1990, pages 126-128 and 228-234.
	AR	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).